CDK12/CDK13: Novel Small Molecule Dual Inhibitors for CDK12/CDK13 for the Treatment of Triple Negative Breast Cancer

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596

19MB064N